RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Oncopeptides - Stock

Oncopeptides Market capitalization 2024

Oncopeptides Market capitalization

366.55 M SEK

Ticker

ONCO.ST

ISIN

SE0009414576

WKN

A2DLU2

In 2024, Oncopeptides's market cap stood at 366.55 M SEK, a -66.09% increase from the 1.08 B SEK market cap in the previous year.

The Oncopeptides Market capitalization history

YEARREVENUE (undefined SEK)GROSS MARGIN (%)NET INCOME (undefined SEK)
2027e514.977,05-
2026e30611,86-
2025e203.3217,85-
2024e85.6842,37-
202335.22103,06-
20228.3699,93-
2021118.355,09-
2020---
2019---
2018---
2017---
2016---
2015---
2014---

Oncopeptides Aktienanalyse

What does Oncopeptides do?

Oncopeptides AB is a biopharmaceutical company specializing in the research and development of novel therapeutics for the treatment of cancer. The company was founded in 2000 in Uppsala, Sweden. Oncopeptides' research focuses on the discovery of substances that can affect specific cellular processes, inhibiting or even killing the growth of cancer cells. The company places particular emphasis on the development of drugs that can be targeted against specific types of cancer and have minimal side effects. The business model of Oncopeptides is based on licensing developed drugs to other companies or marketing their own products. This allows for faster progress in development and minimizes entrepreneurial risk. The company is divided into three different divisions, focusing on different types of cancer. The first division specializes in the treatment of multiple myeloma, the second in the treatment of solid tumors, and the third in the development of diagnostic tests for early cancer detection. The first product that Oncopeptides has brought to market is the drug Ygalo. It is used to treat patients with advanced multiple myeloma who do not respond to other therapies. Ygalo is a peptide mimetic specifically designed to inhibit the protein MCL-1, which plays a key role in cell proliferation in many types of cancer. In the second division of Oncopeptides, the company focuses on the development of drugs that can be specifically targeted against solid tumors such as lung, breast, or colorectal cancer. The protein BET inhibitor is targeted, which plays an important role in the regulation of gene expression in many types of cancer. The third division of Oncopeptides is engaged in the development of diagnostic tests that enable early detection of cancer. Both blood tests and imaging techniques are used to detect changes in the body that could indicate cancer. The focus is on the development of tests that can detect early signs of cancer, enabling timely diagnosis and treatment. Overall, Oncopeptides is a promising company specializing in the development of innovative therapeutics in cancer treatment. With its focus on specific cellular processes and targeted approaches to fighting different types of cancer, the company is on a promising path to bring more products to market that can improve the lives of many cancer patients. Oncopeptides ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Oncopeptides's Market Capitalization

Oncopeptides's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Oncopeptides's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Oncopeptides's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Oncopeptides’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Oncopeptides Stock

What is the current Oncopeptides market capitalization?

The current market capitalization of Oncopeptides is 366.55 M SEK.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Oncopeptides.

How has the market capitalization of Oncopeptides developed in recent years?

The market capitalization of Oncopeptides has increased/decreased by -66.09% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Oncopeptides?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Oncopeptides?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Oncopeptides have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Oncopeptides pay?

Over the past 12 months, Oncopeptides paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Oncopeptides is expected to pay a dividend of 0 SEK.

What is the dividend yield of Oncopeptides?

The current dividend yield of Oncopeptides is .

When does Oncopeptides pay dividends?

Oncopeptides pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Oncopeptides?

Oncopeptides paid dividends every year for the past 0 years.

What is the dividend of Oncopeptides?

For the upcoming 12 months, dividends amounting to 0 SEK are expected. This corresponds to a dividend yield of 0 %.

In which sector is Oncopeptides located?

Oncopeptides is assigned to the 'Health' sector.

Wann musste ich die Aktien von Oncopeptides kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Oncopeptides from 6/22/2024 amounting to 0 SEK, you needed to have the stock in your portfolio before the ex-date on 6/22/2024.

When did Oncopeptides pay the last dividend?

The last dividend was paid out on 6/22/2024.

What was the dividend of Oncopeptides in the year 2023?

In the year 2023, Oncopeptides distributed 0 SEK as dividends.

In which currency does Oncopeptides pay out the dividend?

The dividends of Oncopeptides are distributed in SEK.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Oncopeptides

Our stock analysis for Oncopeptides Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Oncopeptides Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.